Why the study?
Does metformin reduce left ventricular hypertrophy in patients with coronary artery disease without diabetes?
Does metformin reduce left ventricular hypertrophy in patients with coronary artery disease without diabetes?
Metformin significantly reduces surrogate markers of cardiovascular risk, including left ventricular mass and blood pressure, in non-diabetic patients with coronary artery disease.
Supports metformin for LVH regression in non-diabetic CAD; extends its cardiovascular benefits beyond diabetes.
Metformin treatment significantly reduced LVMI, LVM, office systolic BP, body weight, and oxidative stress. Although LVH is a good surrogate marker of cardiovascular (CV) outcome, conclusive evidence for the cardio-protective role of metformin is required from large CV outcomes trials.
No takes yet. Share an insight, caveat, or question.
Mohan et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: